Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P04062
UPID:
GBA1_HUMAN
Alternative names:
Acid beta-glucosidase; Alglucerase; Beta-glucocerebrosidase; Beta-glucosylceramidase 1; Cholesterol glucosyltransferase; Cholesteryl-beta-glucosidase; D-glucosyl-N-acylsphingosine glucohydrolase; Glucosylceramidase beta 1; Imiglucerase; Lysosomal cholesterol glycosyltransferase; Lysosomal galactosylceramidase; Lysosomal glycosylceramidase
Alternative UPACC:
P04062; A8K796; B7Z5G2; B7Z6S1; J3KQG4; J3KQK9; Q16545; Q4VX22; Q6I9R6; Q9UMJ8
Background:
Lysosomal acid glucosylceramidase, known by names such as Acid beta-glucosidase and Imiglucerase, plays a pivotal role in the lysosomal degradation of glucosylceramide into ceramide and glucose. This enzyme is essential for the turnover of cellular membranes and the metabolism of complex lipids.
Therapeutic significance:
Mutations in this enzyme lead to Gaucher disease, a lysosomal storage disorder with varying forms and severities, including neuronopathic and non-neuronopathic types. Its involvement in Parkinson disease highlights its broader impact on neurodegenerative disorders, making it a target for therapeutic intervention.